<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Regulation of erythropoiesis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Regulation of erythropoiesis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Regulation of erythropoiesis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Colin A Sieff, MB, BCh, FRCPath</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Brodsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The production of erythrocytes is a tightly regulated process. During steady state hematopoiesis, approximately 10<sup>10</sup> red blood cells are produced per hour in the bone marrow to maintain the hemoglobin level within fairly narrow limits. Production can be rapidly increased in the setting of ongoing blood loss or hemolysis.</p><p>This topic review will discuss the elements that underlie erythropoiesis. A general discussion of hematopoiesis and stem cell function is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3536.html" rel="external">"Overview of hematopoietic stem cells"</a>.)</p><p class="headingAnchor" id="H50387"><span class="h1">OVERVIEW OF ERYTHROPOIESIS</span><span class="headingEndMark"> — </span>Erythropoiesis begins with the differentiation of multipotent hematopoietic stem cells (HSC) into the most primitive erythroid progenitors  (<a class="graphic graphic_figure graphicRef70092" href="/z/d/graphic/70092.html" rel="external">figure 1</a>). In the classical hematopoietic hierarchy, HSC progeny can differentiate into a common myeloid progenitor (CMP), which in turn differentiates into the common megakaryocyte-erythroid progenitor cell (MEP). </p><p>Studies in humans and mouse models using transplantation and single-cell lineage tracing have shown that the MEPs may derive directly from HSCs [<a href="#rid1">1,2</a>]. MEPs give rise to the erythroid progenitor cells, which subsequently follow a differentiation program that culminates in the emergence of mature erythrocytes. (See <a class="local">'Erythroid progenitor cells'</a> below.) </p><p>The existence of an MEP explains why iron deficiency is associated not only with anemia but frequently with thrombocytosis as well. Iron metabolism is an evolutionarily highly conserved process. Data from mouse models show that an iron-deficient diet or knockout of the gene that is altered in iron-refractory iron deficiency anemia (IRIDA), <em>TMPRSS6</em>, have thrombocytosis [<a href="#rid3">3</a>]. The mechanism was found to involve increased flux of progenitor cells through MEPs, with evidence for attenuation of extracellular signal-regulated kinase (ERK) phosphorylation. This mechanism illustrates an example of extracellular influences on progenitor cell fate. </p><p class="bulletIndent1"><span class="glyph">●</span>This process is driven by successive combinations of transcription factors that dictate the expression of adhesion and hematopoietic growth factor receptors (HGFRs). (See <a class="local">'Transcription factors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adhesion receptors play an important role in the localization and release of maturing cells from specific niches in bone marrow. (See <a class="local">'Stroma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematopoietic growth factors (HGFs), such as interleukin 3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and stem cell factor (SCF, also called Kit ligand or Steel factor), are important for the amplification of progenitor cells. (See <a class="local">'Growth factors'</a> below.)</p><p></p><p>Erythropoietin (EPO) is a growth factor essential for the amplification and terminal differentiation of erythroid progenitors and precursors. Information concerning the control of EPO expression by hypoxia has provided insight into the regulation of erythropoiesis. (See <a class="local">'Hypoxia and EPO expression'</a> below and  <a class="medical medical_review" href="/z/d/html/7106.html" rel="external">"Molecular pathogenesis of congenital erythrocytoses and polycythemia vera", section on 'Oxygen sensor'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ERYTHROID PROGENITOR CELLS</span><span class="headingEndMark"> — </span>The erythroid progenitor compartment of the bone marrow is invisible upon inspection by light microscopy. These committed single lineage progenitors are derived from the stochastic differentiation of bipotential or multipotential progenitors, which emerged from a tiny population of stem cells  (<a class="graphic graphic_figure graphicRef70092" href="/z/d/graphic/70092.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>]. The two sets of erythroid progenitors described below, burst-forming units of the erythroid lineage and colony-forming units of the erythrocyte lineage (BFU-E and CFU-E), cannot be identified by specific morphological features, although they have been purified and analyzed using flow cytometric methods [<a href="#rid5">5</a>]. Evidence suggests that all hematopoietic progenitors or stem cells resemble lymphoblasts [<a href="#rid6">6-8</a>].</p><p class="headingAnchor" id="H11334197"><span class="h2">Erythroid burst-forming unit</span><span class="headingEndMark"> — </span>In humans, the most primitive single lineage committed erythroid progenitor is the erythroid burst-forming unit (BFU-E). These cellular clusters are so named because they have the following characteristics in semisolid in vitro cultures:</p><p class="bulletIndent1"><span class="glyph">●</span>The colonies have a burst-like morphology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In response to the combination of EPO and one of SCF, IL-3, or GM-CSF, the progeny of the first few cellular divisions are motile and form subpopulations of erythroid colony-forming units (CFU-E) [<a href="#rid9">9</a>]. Each of these units subsequently forms a large colony of proerythroblasts, which mature into erythroblasts and a few enucleated erythrocytes.</p><p></p><p>The entire process requires approximately two weeks in vitro.</p><p class="headingAnchor" id="H11334203"><span class="h2">Erythroid colony-forming unit</span><span class="headingEndMark"> — </span>Bone marrow also contains the more mature erythroid colony-forming unit (CFU-E) that, under the influence of EPO, form small colonies of erythroblasts in seven days of culture.</p><p class="headingAnchor" id="H3"><span class="h1">PRECURSORS AND MATURE CELLS</span><span class="headingEndMark"> — </span>The erythroid precursor or erythroblast pool represents about one-third of the marrow cell population in the normal child (above the age of three) and the adult. Proerythroblasts are the earliest recognizable forms  (<a class="graphic graphic_picture graphicRef68933" href="/z/d/graphic/68933.html" rel="external">picture 1</a>). These cells divide and mature through basophilic, polychromatic, and orthochromatic normoblast cells to form the reticulocyte and finally to the circulating mature erythrocyte; this process involves a reduction in cell size, nuclear condensation and extrusion, and hemoglobin accumulation  (<a class="graphic graphic_figure graphicRef55127" href="/z/d/graphic/55127.html" rel="external">figure 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>On average, each proerythroblast can form approximately eight reticulocytes. The mean transit time from proerythroblast to the emergence of the reticulocyte into the circulation is approximately five days [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the circulation, the reticulocyte takes approximately one day to become the mature erythrocyte  (<a class="graphic graphic_figure graphicRef61552" href="/z/d/graphic/61552.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The lifespan in the circulation of the mature erythrocyte is approximately four months. (See  <a class="medical medical_review" href="/z/d/html/7082.html" rel="external">"Red blood cell survival: Normal values and measurement", section on 'Historical methods for determining RBC lifespan'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Acute anemia</span><span class="headingEndMark"> — </span>In acute anemia, the length of this transit time may decrease to as little as one or two days because of skipped divisions [<a href="#rid11">11</a>]. In this setting, the red cells that emerge are macrocytic; they may also bear surface i antigen because they have had insufficient time to convert i antigen to I antigen [<a href="#rid12">12</a>]. They have other fetal characteristics such as increased fetal hemoglobin (Hb F); this results from an increase in differentiation from burst-forming units of the erythroid lineage (BFU-E), which have higher Hb F expression than colony-forming units of the erythroid lineage (CFU-E). The cells also contain excessive burdens of the debris that normally accumulates during cell assembly [<a href="#rid13">13,14</a>]. As a result, stress erythropoiesis is associated with circulating Pappenheimer bodies (iron granules), basophilic stippling (ribosomes), Heinz bodies (hemoglobin inclusions), and Howell-Jolly bodies (nuclear remnants)  (<a class="graphic graphic_picture graphicRef71989 graphicRef60588" href="/z/d/graphic/71989.html" rel="external">picture 2A-B</a>).</p><p class="headingAnchor" id="H5"><span class="h1">STROMA</span><span class="headingEndMark"> — </span>The bone marrow stroma consists of fibroblastoid cells, endothelial cells, and macrophages that comprise the hematopoietic microenvironment [<a href="#rid15">15,16</a>]. Interaction between receptors on erythrocyte precursors and elements of the stromal matrix are important determinants of erythroid maturation. As an example, murine erythroleukemia cells bind specifically to the extracellular matrix protein fibronectin [<a href="#rid17">17</a>]; induction of differentiation of these cells subsequently leads to loss of adhesion. Binding to fibronectin involves very late antigen (VLA)-5, an erythroid integrin that is expressed on erythroid cells and is lost at the reticulocyte stage of development. VLA-5 binds to a specific peptide in the fibronectin molecule, Arg-Gly-Asp-Ser (RGDS) [<a href="#rid18">18</a>].</p><p>Normal burst-forming units of the erythroid lineage (BFU-E) bind preferentially to a stromal fibroblast cell strain [<a href="#rid19">19</a>]; after binding, these cells proliferate and differentiate in the presence of EPO alone [<a href="#rid19">19</a>]. This interaction is blocked by antibodies specific for the cell binding domain of fibronectin, which contains the RGDS sequence [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H2516876"><span class="h2">Macrophages</span><span class="headingEndMark"> — </span>Interactions between developing erythroid cells and macrophages are also important [<a href="#rid20">20-25</a>]. This is classically exemplified by the "erythroblastic island", composed of developing erythroblasts surrounding a central macrophage [<a href="#rid25">25</a>]. These macrophages make physical contacts with developing erythroblasts, enabling signaling and the transfer of growth factors and nutrients (eg, iron) to these cells [<a href="#rid26">26</a>].</p><p>Deoxyribonuclease II from these macrophages may be required for the process through which mature red cells lose their nuclei [<a href="#rid27">27</a>]. In addition, Rac GTPases play an essential role in enucleation through activation of the formin mDia2, which nucleates unbranched actin filaments leading to formation of the contractile actin ring [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H6"><span class="h1">TRANSCRIPTION FACTORS</span><span class="headingEndMark"> — </span>Much has been learned about the essential roles of several transcription factors via the study of their activation in leukemic translocations and the effect of gene disruption in embryonic stem cells [<a href="#rid29">29</a>]. Important factors that most likely act at the level of hematopoietic stem cells include TAL1/SCL, LMO2/RBTN2, and GATA2, while GATA1, FOG1 and EKLF are more important for erythropoiesis  (<a class="graphic graphic_figure graphicRef70092" href="/z/d/graphic/70092.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H7"><span class="h2">TAL1/SCL</span><span class="headingEndMark"> — </span>T-cell acute lymphocytic leukemia 1 (TAL1; also called stem cell leukemia [SCL]) transcription factor is expressed in leukemias (biphenotypic [lymphoid/myeloid] and T cell) [<a href="#rid30">30,31</a>], primitive hematopoietic progenitors, and more mature erythroid, mast, megakaryocyte, and endothelial cells [<a href="#rid32">32,33</a>]. Targeted disruption of this gene in mice leads to death in utero from the absence of blood formation. This finding, together with lack of in vitro myeloid colony formation [<a href="#rid34">34,35</a>], and data indicating that TAL1 contribute to angiogenesis [<a href="#rid36">36</a>], suggest a very early role for TAL1, most likely at the pluripotent or myeloid-erythroid stem cell level. Interestingly, conditional gene targeting in adult mice shows that TAL1 is not required for engraftment and self-renewal of adult stem cells, but is required for differentiation of erythroid and megakaryocyte lineages [<a href="#rid37">37</a>]. Overexpression of this factor in erythroid or bipotent cell lines produces an increase in erythroid differentiation [<a href="#rid38">38,39</a>], but there are no data on overexpression in adult hematopoietic stem cells.</p><p class="headingAnchor" id="H8"><span class="h2">LMO2/RBTN2</span><span class="headingEndMark"> — </span>Another transcription factor implicated in T cell acute lymphoblastic leukemia is the LIM-only domain nuclear protein 2 (LMO2; also called rhombotin 2 [RBTN2]) [<a href="#rid40">40,41</a>]. Mice that lack this factor die in utero and have the same bloodless phenotype as animals that lack TAL1 [<a href="#rid42">42</a>]. Although LMO2 does not show sequence-specific DNA binding, immunoprecipitates in erythroid cells reveal that LMO2 exists in a complex with TAL1 [<a href="#rid43">43,44</a>], thereby suggesting a physiologic interaction in vivo.</p><p class="headingAnchor" id="H9"><span class="h2">GATA2</span><span class="headingEndMark"> — </span>GATA2 is expressed in the regions of Xenopus and Zebrafish embryos that are fated to become hematopoietic and is highly expressed in progenitor cells [<a href="#rid33">33,45-47</a>]. Overexpression of GATA2 in chicken erythroid progenitors leads to proliferation at the expense of differentiation [<a href="#rid48">48</a>].</p><p>On the other hand, targeted disruption of the <em>GATA2</em> gene leads to reduced primitive hematopoiesis in the yolk sac and embryonic death by day 10 to 11 [<a href="#rid49">49</a>]. Definitive hematopoiesis in liver and bone marrow is profoundly reduced with loss of virtually all lineages, and in vitro differentiation data reveal a marked deficiency of SCF-responsive definitive erythroid and mast cell colonies and reduced macrophage colonies. This finding suggests that GATA2 serves as a regulator of genes that control hematopoietic growth factor responsiveness or proliferation of stem and/or early progenitor cells.</p><p>The importance of GATA2 to hematopoiesis and lymphopoiesis has been brought into sharp focus by the discovery that heterozygous mutations in GATA2 are the cause of a broad spectrum of previously described syndromes including monocytopenia and non-tuberculous mycobacterial infections, usually Mycobacterium avium complex, (monoMAC syndrome); dendritic cell, monocyte, B and NK lymphoid deficiency; familial myelodysplastic syndrome (MDS) and acute myeloid leukemia; and Emberger syndrome (lymphedema and MDS). In addition, susceptibility to human papilloma virus, chronic neutropenia, aplastic anemia, and pulmonary alveolar proteinosis have also been described [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'GATA2 deficiency (MonoMAC syndrome)'</a> and  <a class="medical medical_review" href="/z/d/html/3949.html" rel="external">"NK cell deficiency syndromes: Clinical manifestations and diagnosis", section on 'Autosomal dominant GATA2 deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia", section on 'GATA2 deficiency/MonoMAC syndrome'</a>.)</p><p>The finding of markedly decreased expression of GATA2 mRNA in CD34+ cells in patients with aplastic anemia suggests that an aberrant expression of this transcription factor may have been an early description of this disease [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H10"><span class="h2">GATA1</span><span class="headingEndMark"> — </span>GATA1 expression is limited to multipotent progenitors and to erythroid, megakaryocyte, mast, and eosinophil lineages [<a href="#rid52">52-55</a>]. Analysis of chimeric mice injected at the blastocyst stage with <em>GATA1</em><sup>-/-</sup> embryonic stem cells reveals a failure of such cells to contribute to erythrocyte development; however, they can contribute to other hematopoietic lineages and tissues [<a href="#rid56">56,57</a>]. Differentiation assays in vitro show proerythroblast arrest and apoptosis of these cells [<a href="#rid58">58-60</a>].</p><p>Mouse embryos lacking GATA1 die because of severe anemia secondary to arrested maturation of primitive erythroid cells, while GATA1 loss in adult mice results in a condition resembling pure red cell aplasia in humans [<a href="#rid61">61</a>].</p><p>Clinically, a constitutional pathogenic variant in <em>GATA1</em> that interferes with the interaction with its essential cofactor FOG1 (friend of GATA1) is associated with familial dyserythropoietic anemia, defective megakaryocyte maturation, and macrothrombocytopenia [<a href="#rid62">62</a>]. Infants with trisomy 21 and transient myeloproliferative disorder (TMD) or acute megakaryoblastic leukemia (AMKL) have acquired mutations in the 5' region of <em>GATA1</em> that lead to a N-terminal truncated GATA1 protein [<a href="#rid63">63,64</a>]. These variants are almost always present at birth, and therefore acquired in utero, and have also been noted in approximately 10 percent of neonates with trisomy 21 and no evidence of TMD or AMKL [<a href="#rid65">65</a>]. It remains to be seen whether such infants will go on to develop AMKL. (See  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Congenital dyserythropoietic anemia'</a> and  <a class="medical medical_review" href="/z/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis", section on 'Hematologic disorders'</a> and  <a class="medical medical_review" href="/z/d/html/6672.html" rel="external">"Megakaryocyte biology and platelet production", section on 'GATA1 and NF-E2 transcription factors'</a>.)</p><p>Germline mutations in <em>GATA1</em> that also lead to loss of exon 2 and truncation of the N-terminus of GATA1 were discovered in a small proportion of males with Diamond-Blackfan anemia. These mutations lead to synthesis of a short form of GATA1 that is impaired in its ability to drive erythroid differentiation [<a href="#rid66">66</a>]. Whether the more common ribosomal protein gene mutations that account for approximately 60 percent of cases are related in some way to GATA1 deficiency was an open question, but compelling evidence from a 2014 in vitro study demonstrates that GATA1 translation is impaired in cells from Diamond-Blackfan anemia patients with different ribosomal protein gene mutations because ribosomes are limiting [<a href="#rid67">67</a>]. Ribosome deficiency adversely affects the translation of complex structured mRNAs that have low initiation rates [<a href="#rid68">68</a>]. <em>GATA1</em> has a complex 5' untranslated region (UTR) that predicts poor translation initiation rates, and such mRNAs are more sensitive to ribosome deficiency than mRNAs with high initiation rates [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Diamond-Blackfan anemia'</a>.)</p><p>Whether precursor stem cells commit to erythroid or myeloid lineages may depend in part upon interactions between the GATA proteins (both GATA1 and GATA2) and PU.1 (Spi-1), a transcription factor essential for the development of myeloid cells. PU.1 appears to interact with a zinc finger domain of the GATA proteins via a helix-turn-helix wing [<a href="#rid70">70</a>]; this interaction appears to inhibit PU.1 activation of critical myeloid genes, as well as GATA transactivating functions, thereby suggesting that these effects have a role in the commitment of cells to either the erythroid or myeloid lineage.</p><p class="headingAnchor" id="H64529318"><span class="h2">Krϋppel-like factor 1</span><span class="headingEndMark"> — </span>The Krϋppel-like factor 1 (KLF1) transcription factor is a master regulator of terminal erythroid differentiation, controlling expression of many key erythroid pathways and structures, including cell division, the cell membrane and cytoskeleton, iron metabolism, and heme and globin synthesis. KLF1 was found to bind to the beta-globin promoter [<a href="#rid71">71</a>]; it controls globin expression and some aspects of erythroid development. In addition to activating beta-globin expression, KLF1 plays a role in silencing gamma-globin expression, probably by regulating BCL11A and its interaction with Sox6 at the level of the gamma-globin gene [<a href="#rid72">72-74</a>]. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Biology of Hb F'</a> and  <a class="medical medical_review" href="/z/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a>.)</p><p>Heterozygous variants in <em>KLF1</em> are characterized by hereditary persistence of fetal hemoglobin (HPFH) [<a href="#rid72">72</a>] and/or congenital dyserythropoietic anemia (CDE) type IV [<a href="#rid75">75</a>]. However, most monoallelic <em>KLF1</em> mutations give rise to benign phenotypes, including significant increases in levels of Hb F and Hb A2, which may ameliorate the clinical severity of beta thalassemia [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Hereditary persistence of fetal hemoglobin (HPFH)'</a>.) </p><p>In contrast, compound heterozygous variants in the <em>KLF1</em> gene have been associated with an unusual hereditary persistence of embryonic globin synthesis, as well as a wide variety of hematologic abnormalities including a thalassemic phenotype with hypochromia, microcytosis, target cells, fragments and anisopoikilocytosis; a picture suggestive of chronic non-spherocytic hemolytic anemia with schistocytes, fragmented cells and acanthocytes, and pyruvate kinase deficiency; and hydrops fetalis in a neonate with compound heterozygosity for null mutations in KLF1 [<a href="#rid77">77-79</a>]. </p><p class="headingAnchor" id="H11"><span class="h1">GROWTH FACTORS</span><span class="headingEndMark"> — </span>The regulation of the proliferation and maturation of erythroid progenitors depends upon interaction with a number of growth factors. The availability of pure recombinant growth factors, enrichment of target progenitor cells, use of defined "serum-free" culture conditions, and the targeted disruption of factors and their receptors have provided insights into the role of these factors during hematopoiesis.</p><p class="headingAnchor" id="H12"><span class="h2">Erythropoietin</span><span class="headingEndMark"> — </span>Erythropoietin (EPO) is essential for the terminal maturation of erythroid cells [<a href="#rid80">80</a>]. Its major effect appears to be at the level of the CFU-E during adult erythropoiesis; recombinant preparations are as effective as the natural hormone [<a href="#rid81">81-84</a>]. (See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1935.html" rel="external">"Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease"</a>.)</p><p>CFU-E do not survive in vitro in the absence of EPO. Since the majority of CFU-E are cycling, their survival in the presence of EPO may be tightly linked to their proliferation and differentiation to mature erythrocytes.</p><p>EPO also acts upon a subset of presumptive mature burst-forming units of the erythroid lineage (BFU-E), which requires EPO for survival and terminal maturation. A second subset of BFU-E, presumably less mature, survive EPO deprivation if other hematopoietic growth factors such as IL-3 or GM-CSF are present [<a href="#rid85">85</a>].</p><p>Since EPO is crucial for the terminal differentiation of erythroid progenitors, mice with homozygous null mutations of the <em>EPO</em> or EPO receptor (<em>EPOR</em>) genes form BFU-E and CFU-E normally but these BFU-E and CFU-E fail to differentiate into mature erythrocytes [<a href="#rid86">86</a>]. Both the <em>EPO</em><sup>-/-</sup> and <em>EPOR</em><sup>-/-</sup> mutations are embryonically lethal due to failure of definitive (fetal liver) erythropoiesis. However, yolk sac erythropoiesis is only partially impaired, indicating the existence of a population of EPO-independent primary erythropoietic precursors.</p><p>Insight into the molecular mechanism by which EPO prevents apoptosis in erythroid cells comes from studies of the signal transducer and activator of transcription 5 (STAT 5) proteins. <em>STAT5A</em><sup>-/-</sup> <em>STAT5B</em><sup>-/-</sup> mouse embryos are severely anemic during fetal development; the erythroid progenitors in fetal liver are reduced in number and show increased apoptosis [<a href="#rid87">87</a>]. This result was explained by the finding that STAT5 mediates the early induction of the anti-apoptotic gene <em>BCLXL</em> through direct binding to its promoter. Although adult animals were thought to be hematologically normal, about one-half have chronic anemia with splenomegaly, due to an increase in early erythroid precursors; erythropoiesis is ineffective because of an increase in apoptosis in early normoblasts showing reduced levels of BCLXL [<a href="#rid88">88</a>]. In contrast, dominant gain-of-function mutations in the EPOR due to truncation of the cytoplasmic portion of the receptor lead to familial erythrocytosis (type 1) [<a href="#rid89">89</a>] because of elimination of the negative regulatory domain of the receptor that binds an inhibitory phosphatase SH-PTP-1 [<a href="#rid90">90</a>].</p><p>Insight into biased signaling downstream of the EPOR comes from study of a recessively inherited R150Q mutation of <em>EPO</em> [<a href="#rid91">91</a>]. This mutation was found in a transfusion-dependent child thought initially to have Diamond-Blackfan anemia who unexpectedly did not experience improvement after a matched related hematopoietic stem cell transplant. The mutation results in alterations in the kinetics of binding of EPO to the EPOR, with an increased on-rate and a markedly increased off-rate. This results in suboptimal JAK2 phosphorylation, which is essential for STAT5 activation. Perhaps surprisingly, STAT5 activation by JAK2 showed equivalent phosphorylation in response to wild type and mutant EPO, whereas STAT1 and STAT3 activation were both reduced, indicating a bias in the signal output from the mutant receptor.</p><p class="headingAnchor" id="H13"><span class="h2">Stem cell factor</span><span class="headingEndMark"> — </span>Although stem cell factor (SCF) alone has no colony-forming ability, it has marked synergistic effects on BFU-E cultured in the presence of EPO [<a href="#rid92">92-95</a>]. SCF is crucial for the normal development of CFU-E, since mice that lack SCF (Steel mutants) or its receptor KIT (White spotting or W mutants) are severely anemic and have a reduction in fetal liver CFU-E [<a href="#rid96">96</a>]. Studies of cell lines that express both KIT and EPOR (HCD57 cells) or are transduced with cDNAs for these two receptors (32D cells) demonstrate that SCF supports the proliferation of these cells only if the EPOR is also present [<a href="#rid97">97</a>].</p><p>In vitro, SCF induces tyrosine phosphorylation of the EPOR and KIT associates with the cytoplasmic domain of the tyrosine phosphorylated EPOR. Whether such an interaction between KIT and the EPOR occurs during normal erythropoiesis is not known.</p><p class="headingAnchor" id="H14"><span class="h2">IL-3 and GM-CSF</span><span class="headingEndMark"> — </span>Interleukin 3 (IL-3) and GM-CSF receptors share a common beta chain. Both cytokines enhance erythropoietin-dependent in vitro erythropoiesis by primary hematopoietic progenitors and factor-dependent cells. The beta chain interacts functionally and physically with the EPOR, thereby providing an explanation for the synergistic effects of IL-3 and GM-CSF on EPO-driven erythropoiesis [<a href="#rid98">98</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Insulin and insulin-like growth factor 1</span><span class="headingEndMark"> — </span>Factors distinct from the classical colony-stimulating factors may positively regulate erythropoiesis, either directly or indirectly. Limiting dilution studies of highly purified CFU-E in serum-free culture show that insulin and insulin-like growth factor 1 (IGF-1) act directly on these cells in the presence of EPO [<a href="#rid99">99</a>]. By comparison, earlier murine studies of unfractionated cells found that CFU-E respond to IGF-1 or insulin in the absence of EPO [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H24105025"><span class="h2">TGF-beta gene family</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene family members</strong> – This gene family comprises several TGF-beta and bone morphogenic proteins (BMPs), growth and differentiation factors (GDFs), and activin and inhibin. Their receptors comprise two members of the serine/threonine kinase gene family. Activin is the factor produced by vegetal cells during blastogenesis that induces animal ectodermal cells to form primary mesoderm [<a href="#rid101">101</a>]. Activin enhances both BFU-E and CFU-E colony formation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect on erythropoiesis </strong>– This protein dimer (activin plus inhibin), also known as follicle stimulating hormone-releasing protein, appears to have a lineage-specific effect on erythropoiesis that is indirect, since removal of monocytes and/or T lymphocytes abrogates its activity [<a href="#rid102">102</a>]. </p><p></p><p class="bulletIndent1">Murine data suggest that TGF family members may play an intriguing regulatory role during erythropoiesis [<a href="#rid103">103</a>]. Under normal circumstances, GDF11, produced by developing erythroid progenitor cells, inhibits the differentiation of more mature erythroid precursors. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activin and GDF11 ligand traps (</strong><a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">luspatercept</a><strong>)</strong> – Activin and GDF11 ligand traps consist of the extracellular domain of the activin receptor 2A or B linked to an immunoglobulin Fc domain [<a href="#rid104">104</a>]. One possible explanation of the mechanism of action is that luspatercept and other ligand traps alleviate the anemia by removing the GDF11-mediated inhibition of erythroid differentiation. However, SMAD2/3 signaling also decreases the availability of GATA1. Ligand traps may also act by alleviating the sequestration of GATA1 by HSP40, thereby increasing its availability [<a href="#rid105">105</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uses of </strong><a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">luspatercept</a> – In thalassemia and myelodysplastic syndromes (MDS), there is markedly ineffective erythropoiesis, with increased production of GDF11 and consequent decreased erythroid differentiation. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="126108" href="/z/d/drug information/126108.html" rel="external">Luspatercept</a> is approved for transfusion-dependent thalassemia and some forms of MDS [<a href="#rid106">106</a>]. Clinical uses are discussed separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thalassemia</strong> – (See  <a class="medical medical_review" href="/z/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Luspatercept for transfusion-dependent beta thalassemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MDS </strong>– (See  <a class="medical medical_review" href="/z/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Luspatercept'</a> and  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management", section on 'MDS/MPN variants'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Congenital sideroblastic anemias</strong> – (See  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management", section on 'Luspatercept for congenital sideroblastic anemias with ineffective erythropoiesis'</a>.)</p><p></p><p class="headingAnchor" id="H1280406"><span class="h1">MicroRNAs</span><span class="headingEndMark"> — </span>MicroRNAs (miRNAs) are 18 to 25 nucleotide non-protein encoding RNAs that play important roles in the regulation of post transcriptional gene expression by incorporation into an RNA-induced silencing complex (RISC) that contains the Argonaute proteins. The miRNA strand guides RISC typically to complementary sequences in the 3’ untranslated region of target mRNA by Watson Crick base-pairing and leads to either mRNA degradation or translational repression.</p><p>There is strong evidence that miRNAs are important for erythropoiesis. Many miRNAs are expressed in developing erythroid cells [<a href="#rid107">107,108</a>]; most appear to decline in expression level as precursors mature, suggesting that they might regulate the timing of genes important for the synthesis of late erythroid proteins. For example, miR-191 is downregulated, and overexpression in mouse fetal liver cells results in a block in enucleation, a late event in erythropoiesis [<a href="#rid109">109</a>]. Other miRNAs that decrease in expression during differentiation act at an earlier stage of erythropoiesis. Both miR-221 and miR-222 are encoded on a common pre-miRNA; they target and repress KIT expression, so overexpression impairs the proliferation of erythroid precursors [<a href="#rid110">110</a>]. </p><p>Other miRNAs, such as miR-144 and miR-451, increase in expression level during erythropoiesis; both are co-expressed in a bi-cistronic pri-miRNA that is activated by GATA1 [<a href="#rid111">111</a>]. Enforced expression of these two miRs enhances erythropoiesis while depletion of miR-451 has the opposite effect [<a href="#rid107">107,112</a>]. GATA2 is a target of miR-451 in zebrafish [<a href="#rid113">113</a>], and since down-regulation of GATA2 is required for normal erythropoiesis, this might explain the effect of miR-451 depletion. Other experiments suggest that the miR-144/451 effect is more complex, and different mouse models show different phenotypes ranging from an erythroblast block [<a href="#rid114">114</a>] to a hemolytic anemia with an increase in reticulocytes [<a href="#rid115">115</a>]. </p><p class="headingAnchor" id="H18"><span class="h1">HYPOXIA AND EPO EXPRESSION</span><span class="headingEndMark"> — </span>EPO has long been recognized as the physiologic regulator of red cell production [<a href="#rid116">116-119</a>]. It is produced in the kidney and the fetal liver in response to hypoxia or exposure to cobalt chloride.</p><p class="headingAnchor" id="H19"><span class="h2">Hypoxia-inducible factor and the response to hypoxia</span><span class="headingEndMark"> — </span>Specialized interstitial cells in the inner cortex and outer medulla of the kidney respond to hypoxia by producing and secreting EPO. Downstream events from the oxygen sensor involved in activation of EPO gene expression require stabilization and activation of specific transcription factors [<a href="#rid120">120</a>]. One of these is the heterodimeric transcription factor complex hypoxia-inducible factor (HIF-1), comprising both HIF-1-alpha and HIF-1-beta subunits (the dimer is called HIF-1) [<a href="#rid120">120-123</a>].</p><p>While HIF-1-beta is ubiquitously expressed independent of oxygen tension, HIF-1-alpha is only detectable under hypoxic conditions  (<a class="graphic graphic_figure graphicRef53801" href="/z/d/graphic/53801.html" rel="external">figure 4</a>). Above a critical oxygen concentration HIF-1-alpha is ubiquitinated and rapidly degraded in proteosomes. This oxygen sensor in mammalian cells appears to be a proline hydroxylase (prolyl hydroxylase domain proteins PHD1, PHD2, and PHD3) that adds a hydroxyl moiety in an oxygen- and iron-dependent manner to P-564 of HIF-1-alpha; P-564 lies within a highly conserved region of HIF-1-alpha that binds the von Hippel-Lindau (VHL) protein. When P-564 hydroxylated HIF-1-alpha binds VHL, an ubiquitin E3 ligase complex is activated, leading to ubiquitination and subsequent destruction of HIF-1-alpha [<a href="#rid120">120,124-130</a>]. A second related protein, HIF-2-alpha, is also subject to oxygen dependent prolyl hydroxylation, and also dimerizes with HIF-1-beta to form HIF-2. HIF-1-alpha is expressed in all nucleated cells, while HIF-2-alpha expression is restricted to vascular endothelial cells, renal interstitial cells, hepatocytes, cardiomyocytes and astrocytes [<a href="#rid120">120</a>].</p><p>A homozygous R200W mutation of the <em>VHL</em> gene leads to reduction in the interaction of VHL with hydroxylated HIF, accumulation of HIF, and excessive erythrocyte production in Chuvash polycythemia (familial erythrocytosis, type 2) [<a href="#rid131">131</a>]. A different set of dominantly inherited mutations is found in the von Hippel-Lindau syndrome, with loss of the second normal allele in the tumors that characterize this disease. (See  <a class="medical medical_review" href="/z/d/html/5195.html" rel="external">"Molecular biology and pathogenesis of von Hippel-Lindau disease"</a> and  <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia", section on 'Secondary polycythemia'</a> and  <a class="medical medical_review" href="/z/d/html/7106.html" rel="external">"Molecular pathogenesis of congenital erythrocytoses and polycythemia vera", section on 'Chuvash erythrocytosis'</a>.)</p><p>An autosomal dominant form of erythrocytosis occurs with mutations the EGLN1 gene that encodes PHD2 (familial erythrocytosis, type 3) [<a href="#rid132">132</a>]. These mutations may have dominant negative effects because PHD2<sup>+/-</sup> heterozygous mice do not have erythrocytosis.</p><p>Additionally, mutations in the <em>EPAS1</em> gene that encodes HIF-2-alpha can also cause familial erythrocytosis (type 4) [<a href="#rid133">133</a>]. These mutations interfere with the interaction of HIF-2-alpha with PHD2, thereby reducing hydroxylation. Mice with targeted disruption of the <em>EPAS1</em> gene are anemic, emphasizing the importance of HIF-2-alpha in EPO regulation [<a href="#rid134">134</a>].</p><p>HIF-1 activity is induced in a variety of cell types in response to hypoxia or cobalt [<a href="#rid135">135</a>]; this finding suggests that, while HIF-1 is important in the activation of EPO expression, it also plays a role in the activation of other hypoxia-inducible genes, including angiogenesis and glycolysis [<a href="#rid121">121,136-138</a>], and may play a role in the regulation of more than 2 percent of all human genes [<a href="#rid139">139</a>]. HIF-1-alpha may also bind to and negatively regulate the hepcidin promoter, leading to decreased levels of hepcidin [<a href="#rid140">140</a>]. Through coordinate downregulation of hepcidin and upregulation of ferroportin and erythropoietin, the VHL pathway effectively mobilizes iron in support of increased red cell production. (See  <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">"Regulation of iron balance", section on 'Hepcidin'</a>.)</p><p>The activity of HIF-1 is essential for survival. Mice that lack HIF-1 die at midgestation, while heterozygotes, although developmentally normal and similar to normal mice in normoxic conditions, fail to respond adequately to chronic hypoxia [<a href="#rid141">141</a>]. (See  <a class="medical medical_review" href="/z/d/html/2794.html" rel="external">"Overview of angiogenesis inhibitors", section on 'Effect of hypoxia and cytokines'</a>.)</p><p>HIF-1 binds to an enhancer sequence located approximately 130 base pairs downstream from the poly-A addition signal of the EPO gene. This enhancer segment renders other promoter-reporter gene constructs hypoxia-responsive with typical inductions in the range of 4- to 15-fold; this degree of stimulation is significantly less than the 50- to 100-fold induction observed with the chromosomal EPO gene in Hep 3B cells [<a href="#rid142">142</a>].</p><p>Other studies have identified a 53 base pair sequence in the EPO promoter with important regulatory characteristics. This sequence confers oxygen-sensitivity (6- to 10-fold inducibility) to a luciferase reporter gene [<a href="#rid143">143</a>]. The combination of both the enhancer and promoter sequences results in cooperative (50-fold) inducibility of transcription of EPO in response to hypoxia, enhancements approaching that observed in vivo.</p><p class="headingAnchor" id="H20"><span class="h3">Hepatocyte nuclear factor 4 and p300</span><span class="headingEndMark"> — </span>Because both promoter and enhancer sequence elements include the consensus hexanucleotide nuclear hormone receptor response elements, various orphan members of this gene family have been examined for binding to the <em>EPO </em>promoter and enhancer and for their presence in transcription complexes isolated from Hep 3B nuclear extracts. One of these, hepatocyte nuclear factor 4 (HNF-4) is present in these extracts and plays a critical role in hypoxia-induced activation of EPO gene expression in Hep 3B cells [<a href="#rid144">144</a>]. HIF-1a and -1b also bind to a large protein p300 (homologous to the cyclic AMP response element (CREB) binding protein [CBP]) that acts as a general transcriptional activator for a number of genes [<a href="#rid145">145</a>].</p><p>The net effect is that HIF-1a, which accumulates in response to hypoxia, combines with its partner HIF-1b and with HNF-4 and p300 to activate EPO transcription. The role of HIF-2 in this process is under active investigation [<a href="#rid146">146</a>]. (See  <a class="medical medical_review" href="/z/d/html/7106.html" rel="external">"Molecular pathogenesis of congenital erythrocytoses and polycythemia vera", section on 'EPAS1 mutations'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">STRESS AND ERYTHROPOIESIS</span><span class="headingEndMark"> — </span>The level of oxyhemoglobin and the rate of delivery of oxygen to the tissues are the fundamental regulators of erythropoiesis  (<a class="graphic graphic_figure graphicRef53916" href="/z/d/graphic/53916.html" rel="external">figure 5</a>) [<a href="#rid147">147</a>]. In species that package hemoglobin in erythrocytes, erythropoietin mediates the response to oxygen demand; it performs this function by interacting with specific receptors on the surface of mature committed erythroid BFU-E and CFU-E (erythroid burst-forming units and colony-forming units, respectively) [<a href="#rid148">148-152</a>]. As noted above, hypoxia induces a transcriptional increase in expression of the EPO gene via HIF-1a and HIF-1b [<a href="#rid121">121,122</a>].</p><p>BFU-E mature to single CFU-E that divide, and, under the influence of lower concentrations of erythropoietin, form single, relatively small colonies of proerythroblasts in about one week in vitro. The bone marrow of an adult mouse contains about 500 CFU-E per 10<sup>5</sup> nucleated cells. In response to anemic stress, as in hemorrhage or hemolysis, almost the entire burden of accelerated reticulocyte production is borne by the rapid erythropoietin-dependent influx from the progenitor compartment into the proerythroblast pool, resulting in an expanded proerythroblast pool [<a href="#rid153">153</a>].</p><p>Anemic stress produces little or no increase in the mitotic rate of recognizable erythroid precursors [<a href="#rid153">153</a>]. Instead, the following changes are seen:</p><p class="bulletIndent1"><span class="glyph">●</span>The late BFU-E and CFU-E proliferate (because of EPO binding to its receptors) and differentiate to proerythroblasts and beyond. In normal murine marrow, the CFU-E frequency increases from about 500 per 10<sup>5</sup> nucleated cells to 1000 to 2000 CFU-E per 10<sup>5</sup> nucleated cells following experimental hemorrhage or hemolysis. By comparison, hypertransfused mice, in which erythropoiesis is completely suppressed, show an 80 to 90 percent reduction in number of CFU-E.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The orderly progression from immature BFU-E through CFU-E to proerythroblast is interrupted. High erythropoietin levels permit or induce differentiation of progenitors to proerythroblasts. In the rhesus monkey, this premature terminal differentiation may account for the marked increase in fetal hemoglobin content and F cells observed during stress erythropoiesis [<a href="#rid154">154</a>]. In contrast, progenitors in humans have a lesser ability to generate erythroblasts capable of synthesizing large quantities of fetal hemoglobin [<a href="#rid155">155</a>]. As a result, the accumulation of F cells in peripheral blood in response to anemia is relatively small [<a href="#rid156">156</a>]. (See  <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Secondary increases in Hb F'</a>.)</p><p></p><p>Red cells produced under such situations are usually macrocytic and carry the i antigen. However, these two characteristics may relate to a short transit time through the marrow in response to erythropoietin rather than an intrinsic characteristic of fetal hemoglobin-containing cells themselves. Fetal hemoglobin-containing cells (F cells) are also present in very small numbers in the blood of normal individuals, but these cells are not macrocytic and do not bear i antigen. F cell progenitors can be easily detected in the bone marrow of patients with various dyspoieses [<a href="#rid157">157,158</a>] and even in normal marrows [<a href="#rid159">159</a>].</p><p>In mice, stress erythropoiesis appears to occur largely in the spleen, where "stress" BFU-E respond to EPO, SCF, and bone morphogenic protein 4 (BMP4), which signals via the Smad5 pathway; hypoxia increases both BMP expression and the BMP4/Smad5 signaling response [<a href="#rid160">160</a>]. This contrasts with "steady state" bone marrow BFU-E that require only SCF, IL-3/GM-CSF and become responsive to EPO as they mature to CFU-E and proerythroblasts. There is also evidence that Hedgehog signaling replenishes splenic stress BFU-E from the bone marrow BFU-E pool [<a href="#rid161">161</a>].</p><p>Glucocorticoids play an important role in the erythropoietic response to stress and are also the principal treatment for Diamond-Blackfan anemia (DBA). (See  <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Diamond-Blackfan anemia'</a>.)</p><p>Mouse and human studies have shown that glucocorticoids have a greater effect on BFU-E than CFU-E proliferation [<a href="#rid162">162,163</a>]. A major insight into the mechanism of this effect comes from single-cell transcriptome profiling of purified mouse fetal liver erythroid progenitors [<a href="#rid164">164</a>]. These studies show that glucocorticoids enhance erythropoiesis by slowing the transit of early through late BFU-E, without affecting the rate of the cell cycle or asymmetric self-renewal divisions. Rather, the slowed rate of progression allows an increase in the number of cell divisions, thereby increasing output into the CFU-E pool. The mechanism by which this occurs is through prolonged expression of genes such as <em>GATA2</em> that antagonize expression of genes such as <em>GATA1</em> that drive terminal differentiation.</p><p class="headingAnchor" id="H20133062"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Production of red blood cells</strong> – During steady-state hematopoiesis, approximately 10<sup>10</sup> red blood cells are produced per hour in the bone marrow to maintain the hemoglobin level within fairly narrow limits. Production can be rapidly increased in the setting of ongoing blood loss or hemolysis. Erythropoiesis begins with the differentiation of a small pool of multipotent stem cells into primitive erythroid progenitors. These develop into erythroid precursors, culminating in the emergence of mature erythrocytes. (See <a class="local">'Erythroid progenitor cells'</a> above and <a class="local">'Precursors and mature cells'</a> above.)</p><p></p><p class="bulletIndent1">A general discussion of hematopoiesis and hematopoietic stem cell function is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3536.html" rel="external">"Overview of hematopoietic stem cells"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transcription factors</strong> – The erythroid maturation process is driven by transcription factors as well as hematopoietic growth factors and their receptors  (<a class="graphic graphic_figure graphicRef70092" href="/z/d/graphic/70092.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef55127" href="/z/d/graphic/55127.html" rel="external">figure 2</a>). (See <a class="local">'Transcription factors'</a> above and <a class="local">'Growth factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythropoietin</strong> – Erythropoietin (EPO) is the physiologic regulator of red cell production, produced in the kidney and the fetal liver in response to hypoxia due to anemia or other causes  (<a class="graphic graphic_figure graphicRef53801" href="/z/d/graphic/53801.html" rel="external">figure 4</a> and <a class="graphic graphic_figure graphicRef53916" href="/z/d/graphic/53916.html" rel="external">figure 5</a>). (See <a class="local">'Erythropoietin'</a> above and <a class="local">'Hypoxia and EPO expression'</a> above.)</p><p></p><p class="headingAnchor" id="H995685735"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic review and was a founding Editor-in-Chief for UpToDate in Hematology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Guo G, Luc S, Marco E, et al. Mapping cellular hierarchy by single-cell analysis of the cell surface repertoire. Cell Stem Cell 2013; 13:492.</a></li><li><a class="nounderline abstract_t">Notta F, Zandi S, Takayama N, et al. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science 2016; 351:aab2116.</a></li><li><a class="nounderline abstract_t">Xavier-Ferrucio J, Scanlon V, Li X, et al. Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice. Blood 2019; 134:1547.</a></li><li><a class="nounderline abstract_t">Suda T, Suda J, Ogawa M. Disparate differentiation in mouse hemopoietic colonies derived from paired progenitors. Proc Natl Acad Sci U S A 1984; 81:2520.</a></li><li><a class="nounderline abstract_t">Li J, Hale J, Bhagia P, et al. Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E. Blood 2014; 124:3636.</a></li><li><a class="nounderline abstract_t">Emerson SG, Sieff CA, Wang EA, et al. Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity. J Clin Invest 1985; 76:1286.</a></li><li><a class="nounderline abstract_t">Dicke KA, van Noord MJ, Maat B, et al. Identification of cells in primate bone marrow resembling the hemopoietic stem cell in the mouse. Blood 1973; 42:195.</a></li><li><a class="nounderline abstract_t">Rosse C. Small lymphocyte and transitional cell populations of the bone marrow; their role in the mediation of immune and hemopoietic progenitor cell functions. Int Rev Cytol 1976; 45:155.</a></li><li class="breakAll">Axelrad AA, McLeod DL, et al. Properties of cells that produce erythrocytic colonies in vitro. In: Hematopoiesis in Culture, Robinson, WA (Eds), National Institutes of Health, Washington 1974. p.226.</li><li><a class="nounderline abstract_t">Finch CA, Deubelbeiss K, Cook JD, et al. Ferrokinetics in man. Medicine (Baltimore) 1970; 49:17.</a></li><li><a class="nounderline abstract_t">Lord BI. Kinetics of the recognizable erythrocyte precursor cells. Clin Haematol 1979; 8:355.</a></li><li><a class="nounderline abstract_t">Hillman RS, Giblett ER. Red cell membrane alteration associated with "marrow stress". J Clin Invest 1965; 44:1730.</a></li><li><a class="nounderline abstract_t">Nathan DG. Rubbish in the red cell. N Engl J Med 1969; 281:558.</a></li><li><a class="nounderline abstract_t">Etlinger JD, Goldberg AL. Control of protein degradation in reticulocytes and reticulocyte extracts by hemin. J Biol Chem 1980; 255:4563.</a></li><li><a class="nounderline abstract_t">Müller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem cell universe. Stem Cells 1995; 13:477.</a></li><li><a class="nounderline abstract_t">Clark BR, Keating A. Biology of bone marrow stroma. Ann N Y Acad Sci 1995; 770:70.</a></li><li><a class="nounderline abstract_t">Patel VP, Lodish HF. Loss of adhesion of murine erythroleukemia cells to fibronectin during erythroid differentiation. Science 1984; 224:996.</a></li><li><a class="nounderline abstract_t">Patel VP, Lodish HF. The fibronectin receptor on mammalian erythroid precursor cells: characterization and developmental regulation. J Cell Biol 1986; 102:449.</a></li><li><a class="nounderline abstract_t">Tsai S, Patel V, Beaumont E, et al. Differential binding of erythroid and myeloid progenitors to fibroblasts and fibronectin. Blood 1987; 69:1587.</a></li><li><a class="nounderline abstract_t">Hamamura K, Matsuda H, Takeuchi Y, et al. A critical role of VLA-4 in erythropoiesis in vivo. Blood 1996; 87:2513.</a></li><li><a class="nounderline abstract_t">Sadahira Y, Yoshino T, Monobe Y. Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands. J Exp Med 1995; 181:411.</a></li><li><a class="nounderline abstract_t">Yanai N, Sekine C, Yagita H, Obinata M. Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. Blood 1994; 83:2844.</a></li><li><a class="nounderline abstract_t">Rhodes MM, Kopsombut P, Bondurant MC, et al. Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin. Blood 2008; 111:1700.</a></li><li><a class="nounderline abstract_t">Chow A, Huggins M, Ahmed J, et al. CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med 2012; 19:429.</a></li><li><a class="nounderline abstract_t">Chasis JA, Mohandas N. Erythroblastic islands: niches for erythropoiesis. Blood 2008; 112:470.</a></li><li><a class="nounderline abstract_t">Korolnek T, Hamza I. Macrophages and iron trafficking at the birth and death of red cells. Blood 2015; 125:2893.</a></li><li><a class="nounderline abstract_t">Kawane K, Fukuyama H, Kondoh G, et al. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science 2001; 292:1546.</a></li><li><a class="nounderline abstract_t">Ji P, Murata-Hori M, Lodish HF. Formation of mammalian erythrocytes: chromatin condensation and enucleation. Trends Cell Biol 2011; 21:409.</a></li><li><a class="nounderline abstract_t">Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87:4025.</a></li><li><a class="nounderline abstract_t">Begley CG, Aplan PD, Davey MP, et al. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci U S A 1989; 86:2031.</a></li><li><a class="nounderline abstract_t">Finger LR, Kagan J, Christopher G, et al. Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. Proc Natl Acad Sci U S A 1989; 86:5039.</a></li><li><a class="nounderline abstract_t">Begley CG, Aplan PD, Denning SM, et al. The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci U S A 1989; 86:10128.</a></li><li><a class="nounderline abstract_t">Mouthon MA, Bernard O, Mitjavila MT, et al. Expression of tal-1 and GATA-binding proteins during human hematopoiesis. Blood 1993; 81:647.</a></li><li><a class="nounderline abstract_t">Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 1995; 373:432.</a></li><li><a class="nounderline abstract_t">Robb L, Lyons I, Li R, et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc Natl Acad Sci U S A 1995; 92:7075.</a></li><li><a class="nounderline abstract_t">Visvader JE, Fujiwara Y, Orkin SH. Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev 1998; 12:473.</a></li><li><a class="nounderline abstract_t">Mikkola HK, Klintman J, Yang H, et al. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 2003; 421:547.</a></li><li><a class="nounderline abstract_t">Aplan PD, Nakahara K, Orkin SH, Kirsch IR. The SCL gene product: a positive regulator of erythroid differentiation. EMBO J 1992; 11:4073.</a></li><li><a class="nounderline abstract_t">Hoang T, Paradis E, Brady G, et al. Opposing effects of the basic helix-loop-helix transcription factor SCL on erythroid and monocytic differentiation. Blood 1996; 87:102.</a></li><li><a class="nounderline abstract_t">Boehm T, Foroni L, Kaneko Y, et al. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A 1991; 88:4367.</a></li><li><a class="nounderline abstract_t">Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372:143.</a></li><li><a class="nounderline abstract_t">Warren AJ, Colledge WH, Carlton MB, et al. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994; 78:45.</a></li><li><a class="nounderline abstract_t">Valge-Archer VE, Osada H, Warren AJ, et al. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc Natl Acad Sci U S A 1994; 91:8617.</a></li><li><a class="nounderline abstract_t">Wadman I, Li J, Bash RO, et al. Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia. EMBO J 1994; 13:4831.</a></li><li><a class="nounderline abstract_t">Dorfman DM, Wilson DB, Bruns GA, Orkin SH. Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells. J Biol Chem 1992; 267:1279.</a></li><li><a class="nounderline abstract_t">Leonard M, Brice M, Engel JD, Papayannopoulou T. Dynamics of GATA transcription factor expression during erythroid differentiation. Blood 1993; 82:1071.</a></li><li><a class="nounderline abstract_t">Visvader J, Adams JM. Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. Blood 1993; 82:1493.</a></li><li><a class="nounderline abstract_t">Briegel K, Lim KC, Plank C, et al. Ectopic expression of a conditional GATA-2/estrogen receptor chimera arrests erythroid differentiation in a hormone-dependent manner. Genes Dev 1993; 7:1097.</a></li><li><a class="nounderline abstract_t">Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994; 371:221.</a></li><li><a class="nounderline abstract_t">Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014; 123:809.</a></li><li><a class="nounderline abstract_t">Fujimaki S, Harigae H, Sugawara T, et al. Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia. Br J Haematol 2001; 113:52.</a></li><li><a class="nounderline abstract_t">Martin DI, Zon LI, Mutter G, Orkin SH. Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature 1990; 344:444.</a></li><li><a class="nounderline abstract_t">Romeo PH, Prandini MH, Joulin V, et al. Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature 1990; 344:447.</a></li><li><a class="nounderline abstract_t">Zon LI, Yamaguchi Y, Yee K, et al. Expression of mRNA for the GATA-binding proteins in human eosinophils and basophils: potential role in gene transcription. Blood 1993; 81:3234.</a></li><li><a class="nounderline abstract_t">Zheng J, Kitajima K, Sakai E, et al. Differential effects of GATA-1 on proliferation and differentiation of erythroid lineage cells. Blood 2006; 107:520.</a></li><li><a class="nounderline abstract_t">Pevny L, Simon MC, Robertson E, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991; 349:257.</a></li><li><a class="nounderline abstract_t">Simon MC, Pevny L, Wiles MV, et al. Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells. Nat Genet 1992; 1:92.</a></li><li><a class="nounderline abstract_t">Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 1994; 8:1184.</a></li><li><a class="nounderline abstract_t">Pevny L, Lin CS, D'Agati V, et al. Development of hematopoietic cells lacking transcription factor GATA-1. Development 1995; 121:163.</a></li><li><a class="nounderline abstract_t">Weiss MJ, Orkin SH. Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci U S A 1995; 92:9623.</a></li><li><a class="nounderline abstract_t">Gutiérrez L, Tsukamoto S, Suzuki M, et al. Ablation of Gata1 in adult mice results in aplastic crisis, revealing its essential role in steady-state and stress erythropoiesis. Blood 2008; 111:4375.</a></li><li><a class="nounderline abstract_t">Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 2000; 24:266.</a></li><li><a class="nounderline abstract_t">Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32:148.</a></li><li><a class="nounderline abstract_t">Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003; 101:4301.</a></li><li><a class="nounderline abstract_t">Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103:2480.</a></li><li><a class="nounderline abstract_t">Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest 2012; 122:2439.</a></li><li><a class="nounderline abstract_t">Ludwig LS, Gazda HT, Eng JC, et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat Med 2014; 20:748.</a></li><li><a class="nounderline abstract_t">Khajuria RK, Munschauer M, Ulirsch JC, et al. Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis. Cell 2018; 173:90.</a></li><li><a class="nounderline abstract_t">Mills EW, Green R. Ribosomopathies: There's strength in numbers. Science 2017; 358.</a></li><li><a class="nounderline abstract_t">Zhang P, Behre G, Pan J, et al. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc Natl Acad Sci U S A 1999; 96:8705.</a></li><li><a class="nounderline abstract_t">Miller IJ, Bieker JJ. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family of nuclear proteins. Mol Cell Biol 1993; 13:2776.</a></li><li><a class="nounderline abstract_t">Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010; 42:801.</a></li><li><a class="nounderline abstract_t">Zhou D, Liu K, Sun CW, et al. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet 2010; 42:742.</a></li><li><a class="nounderline abstract_t">Tallack MR, Perkins AC. Three fingers on the switch: Krüppel-like factor 1 regulation of γ-globin to β-globin gene switching. Curr Opin Hematol 2013; 20:193.</a></li><li><a class="nounderline abstract_t">Arnaud L, Saison C, Helias V, et al. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet 2010; 87:721.</a></li><li><a class="nounderline abstract_t">Liu D, Zhang X, Yu L, et al. KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia. Blood 2014; 124:803.</a></li><li><a class="nounderline abstract_t">Viprakasit V, Ekwattanakit S, Riolueang S, et al. Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression. Blood 2014; 123:1586.</a></li><li><a class="nounderline abstract_t">Satta S, Perseu L, Maccioni L, et al. Delayed fetal hemoglobin switching in subjects with KLF1 gene mutation. Blood Cells Mol Dis 2012; 48:22.</a></li><li><a class="nounderline abstract_t">Magor GW, Tallack MR, Gillinder KR, et al. KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome. Blood 2015; 125:2405.</a></li><li><a class="nounderline abstract_t">Malik J, Kim AR, Tyre KA, et al. Erythropoietin critically regulates the terminal maturation of murine and human primitive erythroblasts. Haematologica 2013; 98:1778.</a></li><li><a class="nounderline abstract_t">Sieff CA, Emerson SG, Mufson A, et al. Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J Clin Invest 1986; 77:74.</a></li><li><a class="nounderline abstract_t">Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52:1196.</a></li><li><a class="nounderline abstract_t">Eaves AC, Eaves CJ. Erythropoiesis in culture. Clin Haematol 1984; 13:371.</a></li><li><a class="nounderline abstract_t">Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034.</a></li><li><a class="nounderline abstract_t">Sieff CA, Ekern SC, Nathan DG, Anderson JW. Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture. Blood 1989; 73:688.</a></li><li><a class="nounderline abstract_t">Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83:59.</a></li><li><a class="nounderline abstract_t">Socolovsky M, Fallon AE, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98:181.</a></li><li><a class="nounderline abstract_t">Socolovsky M, Nam H, Fleming MD, et al. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001; 98:3261.</a></li><li><a class="nounderline abstract_t">de la Chapelle A, Träskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A 1993; 90:4495.</a></li><li><a class="nounderline abstract_t">Klingmüller U, Lorenz U, Cantley LC, et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80:729.</a></li><li><a class="nounderline abstract_t">Kim AR, Ulirsch JC, Wilmes S, et al. Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation. Cell 2017; 168:1053.</a></li><li><a class="nounderline abstract_t">Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55:1.</a></li><li><a class="nounderline abstract_t">Abkowitz JL, Sabo KM, Nakamoto B, et al. Diamond-blackfan anemia: in vitro response of erythroid progenitors to the ligand for c-kit. Blood 1991; 78:2198.</a></li><li><a class="nounderline abstract_t">Bagnara GP, Zauli G, Vitale L, et al. In vitro growth and regulation of bone marrow enriched CD34+ hematopoietic progenitors in Diamond-Blackfan anemia. Blood 1991; 78:2203.</a></li><li><a class="nounderline abstract_t">Olivieri NF, Grunberger T, Ben-David Y, et al. Diamond-Blackfan anemia: heterogenous response of hematopoietic progenitor cells in vitro to the protein product of the steel locus. Blood 1991; 78:2211.</a></li><li><a class="nounderline abstract_t">Nocka K, Majumder S, Chabot B, et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. Genes Dev 1989; 3:816.</a></li><li><a class="nounderline abstract_t">Wu H, Klingmüller U, Besmer P, Lodish HF. Interaction of the erythropoietin and stem-cell-factor receptors. Nature 1995; 377:242.</a></li><li><a class="nounderline abstract_t">Jubinsky PT, Krijanovski OI, Nathan DG, et al. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997; 90:1867.</a></li><li><a class="nounderline abstract_t">Sawada K, Krantz SB, Dessypris EN, et al. Human colony-forming units-erythroid do not require accessory cells, but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development. J Clin Invest 1989; 83:1701.</a></li><li><a class="nounderline abstract_t">Kurtz A, Jelkmann W, Bauer C. Insulin stimulates erythroid colony formation independently of erythropoietin. Br J Haematol 1983; 53:311.</a></li><li><a class="nounderline abstract_t">Smith JC, Price BM, Van Nimmen K, Huylebroeck D. Identification of a potent Xenopus mesoderm-inducing factor as a homologue of activin A. Nature 1990; 345:729.</a></li><li><a class="nounderline abstract_t">Yu J, Shao L, Vaughan J, et al. Characterization of the potentiation effect of activin on human erythroid colony formation in vitro. Blood 1989; 73:952.</a></li><li><a class="nounderline abstract_t">Paulson RF. Targeting a new regulator of erythropoiesis to alleviate anemia. Nat Med 2014; 20:334.</a></li><li><a class="nounderline abstract_t">Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med 2014; 20:398.</a></li><li><a class="nounderline abstract_t">Cappellini MD, Taher AT. The use of luspatercept for thalassemia in adults. Blood Adv 2021; 5:326.</a></li><li><a class="nounderline abstract_t">Chan O, Komrokji RS. Luspatercept in the treatment of lower-risk myelodysplastic syndromes. Future Oncol 2021; 17:1473.</a></li><li><a class="nounderline abstract_t">Zhan M, Miller CP, Papayannopoulou T, et al. MicroRNA expression dynamics during murine and human erythroid differentiation. Exp Hematol 2007; 35:1015.</a></li><li><a class="nounderline abstract_t">Zhao G, Yu D, Weiss MJ. MicroRNAs in erythropoiesis. Curr Opin Hematol 2010; 17:155.</a></li><li><a class="nounderline abstract_t">Zhang L, Flygare J, Wong P, et al. miR-191 regulates mouse erythroblast enucleation by down-regulating Riok3 and Mxi1. Genes Dev 2011; 25:119.</a></li><li><a class="nounderline abstract_t">Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A 2005; 102:18081.</a></li><li><a class="nounderline abstract_t">Dore LC, Amigo JD, Dos Santos CO, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A 2008; 105:3333.</a></li><li><a class="nounderline abstract_t">Papapetrou EP, Korkola JE, Sadelain M. A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem Cells 2010; 28:287.</a></li><li><a class="nounderline abstract_t">Pase L, Layton JE, Kloosterman WP, et al. miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2. Blood 2009; 113:1794.</a></li><li><a class="nounderline abstract_t">Patrick DM, Zhang CC, Tao Y, et al. Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta. Genes Dev 2010; 24:1614.</a></li><li><a class="nounderline abstract_t">Yu D, dos Santos CO, Zhao G, et al. miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta. Genes Dev 2010; 24:1620.</a></li><li><a class="nounderline abstract_t">Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72:449.</a></li><li><a class="nounderline abstract_t">Blanchard KL, Fandrey J, Goldberg MA, Bunn HF. Regulation of the erythropoietin gene. Stem Cells 1993; 11 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Porter DL, Goldberg MA. Regulation of erythropoietin production. Exp Hematol 1993; 21:399.</a></li><li><a class="nounderline abstract_t">Bunn HF, Gu J, Huang LE, et al. Erythropoietin: a model system for studying oxygen-dependent gene regulation. J Exp Biol 1998; 201:1197.</a></li><li><a class="nounderline abstract_t">Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009; 114:2015.</a></li><li><a class="nounderline abstract_t">Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.</a></li><li><a class="nounderline abstract_t">Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230.</a></li><li><a class="nounderline abstract_t">Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365:537.</a></li><li><a class="nounderline abstract_t">Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998; 95:7987.</a></li><li><a class="nounderline abstract_t">Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275:25733.</a></li><li><a class="nounderline abstract_t">Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673.</a></li><li><a class="nounderline abstract_t">Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001; 107:1.</a></li><li><a class="nounderline abstract_t">Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468.</a></li><li><a class="nounderline abstract_t">Zhu H, Bunn HF. Signal transduction. How do cells sense oxygen? Science 2001; 292:449.</a></li><li><a class="nounderline abstract_t">Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464.</a></li><li><a class="nounderline abstract_t">Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32:614.</a></li><li><a class="nounderline abstract_t">Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A 2006; 103:654.</a></li><li><a class="nounderline abstract_t">Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358:162.</a></li><li><a class="nounderline abstract_t">Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005; 105:3133.</a></li><li><a class="nounderline abstract_t">Weidemann A, Kerdiles YM, Knaup KX, et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest 2009; 119:3373.</a></li><li><a class="nounderline abstract_t">Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269:23757.</a></li><li><a class="nounderline abstract_t">Wykoff CC, Sotiriou C, Cockman ME, et al. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 2004; 90:1235.</a></li><li><a class="nounderline abstract_t">Rathmell WK, Simon MC. VHL: oxygen sensing and vasculogenesis. J Thromb Haemost 2005; 3:2627.</a></li><li><a class="nounderline abstract_t">Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005; 105:659.</a></li><li><a class="nounderline abstract_t">Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117:1926.</a></li><li><a class="nounderline abstract_t">Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999; 103:691.</a></li><li><a class="nounderline abstract_t">Semenza GL, Koury ST, Nejfelt MK, et al. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci U S A 1991; 88:8725.</a></li><li><a class="nounderline abstract_t">Blanchard KL, Acquaviva AM, Galson DL, Bunn HF. Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 1992; 12:5373.</a></li><li><a class="nounderline abstract_t">Galson DL, Tsuchiya T, Tendler DS, et al. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. Mol Cell Biol 1995; 15:2135.</a></li><li><a class="nounderline abstract_t">Arany Z, Huang LE, Eckner R, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 1996; 93:12969.</a></li><li><a class="nounderline abstract_t">Frede S, Freitag P, Geuting L, et al. Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC. Blood 2011; 117:4905.</a></li><li><a class="nounderline abstract_t">GRANT WC, ROOT WS. Fundamental stimulus for erythropoiesis. Physiol Rev 1952; 32:449.</a></li><li><a class="nounderline abstract_t">D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell 1989; 57:277.</a></li><li><a class="nounderline abstract_t">Krantz SB, Goldwasser E. Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus. Proc Natl Acad Sci U S A 1984; 81:7574.</a></li><li><a class="nounderline abstract_t">Sawyer ST, Krantz SB, Sawada K. Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood 1989; 74:103.</a></li><li><a class="nounderline abstract_t">Sawada K, Krantz SB, Sawyer ST, Civin CI. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. J Cell Physiol 1988; 137:337.</a></li><li><a class="nounderline abstract_t">Akahane K, Tojo A, Fukamachi H, et al. Binding of iodinated erythropoietin to rat bone marrow cells under normal and anemic conditions. Exp Hematol 1989; 17:177.</a></li><li><a class="nounderline abstract_t">ALPEN EL, CRANMORE D. Cellular kinetics and iron utilization in bone marrow as observed by Fe59 radioautography. Ann N Y Acad Sci 1959; 77:753.</a></li><li><a class="nounderline abstract_t">Macklis RM, Javid J, Lipton JM, et al. Synthesis of hemoglobin F in adult simian erythroid progenitor-derived colonies. J Clin Invest 1982; 70:752.</a></li><li><a class="nounderline abstract_t">Friedman AD, Linch DC, Miller B, et al. Determination of the hemoglobin F program in human progenitor-derived erythroid cells. J Clin Invest 1985; 75:1359.</a></li><li><a class="nounderline abstract_t">Dover GJ, Boyer SH, Zinkham WH. Production of erythrocytes that contain fetal hemoglobin in anemia. Transient in vivo changes. J Clin Invest 1979; 63:173.</a></li><li><a class="nounderline abstract_t">Kidoguchi K, Ogawa M, Karam JD, Martin AG. Augmentation of fetal hemoglobin (HbF) synthesis in culture by human erythropoietic precursors in the marrow and peripheral blood: studies in sickle cell anemia and nonhemoglobinopathic adults. Blood 1978; 52:1115.</a></li><li><a class="nounderline abstract_t">Clarke BJ, Nathan DG, Alter BP, et al. Hemoglobin synthesis in human BFU-E and CFU-E-derived erythroid colonies. Blood 1979; 54:805.</a></li><li><a class="nounderline abstract_t">Papayannopoulou T, Brice M, Stamatoyannopoulos G. Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells. Proc Natl Acad Sci U S A 1977; 74:2923.</a></li><li><a class="nounderline abstract_t">Harandi OF, Hedge S, Wu DC, et al. Murine erythroid short-term radioprotection requires a BMP4-dependent, self-renewing population of stress erythroid progenitors. J Clin Invest 2010; 120:4507.</a></li><li><a class="nounderline abstract_t">Perry JM, Harandi OF, Porayette P, et al. Maintenance of the BMP4-dependent stress erythropoiesis pathway in the murine spleen requires hedgehog signaling. Blood 2009; 113:911.</a></li><li><a class="nounderline abstract_t">Flygare J, Rayon Estrada V, Shin C, et al. HIF1alpha synergizes with glucocorticoids to promote BFU-E progenitor self-renewal. Blood 2011; 117:3435.</a></li><li><a class="nounderline abstract_t">Narla A, Dutt S, McAuley JR, et al. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood 2011; 118:2296.</a></li><li><a class="nounderline abstract_t">Li H, Natarajan A, Ezike J, et al. Rate of Progression through a Continuum of Transit-Amplifying Progenitor Cell States Regulates Blood Cell Production. Dev Cell 2019; 49:118.</a></li></ol></div><div id="topicVersionRevision">Topic 7161 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24035353" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mapping cellular hierarchy by single-cell analysis of the cell surface repertoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26541609" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Distinct routes of lineage development reshape the human blood hierarchy across ontogeny.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31439541" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6585813" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Disparate differentiation in mouse hemopoietic colonies derived from paired progenitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25339359" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3876355" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4134727" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Identification of cells in primate bone marrow resembling the hemopoietic stem cell in the mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/783066" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Small lymphocyte and transitional cell populations of the bone marrow; their role in the mediation of immune and hemopoietic progenitor cell functions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/783066" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Small lymphocyte and transitional cell populations of the bone marrow; their role in the mediation of immune and hemopoietic progenitor cell functions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4908580" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ferrokinetics in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Kinetics of the recognizable erythrocyte precursor cells</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5214809" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Red cell membrane alteration associated with "marrow stress".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4895382" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rubbish in the red cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7372594" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Control of protein degradation in reticulocytes and reticulocyte extracts by hemin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8528097" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The stromal cells' guide to the stem cell universe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8597383" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Biology of bone marrow stroma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6585955" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Loss of adhesion of murine erythroleukemia cells to fibronectin during erythroid differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2935541" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The fibronectin receptor on mammalian erythroid precursor cells: characterization and developmental regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3580569" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Differential binding of erythroid and myeloid progenitors to fibroblasts and fibronectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630418" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A critical role of VLA-4 in erythropoiesis in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7528776" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7514048" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17993612" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650462" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Erythroblastic islands: niches for erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25778532" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Macrophages and iron trafficking at the birth and death of red cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11375492" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21592797" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Formation of mammalian erythrocytes: chromatin condensation and enucleation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639758" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The transcriptional control of hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2467296" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2740341" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2602361" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7678994" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Expression of tal-1 and GATA-binding proteins during human hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7830794" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7624372" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9472016" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12540851" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1396592" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The SCL gene product: a positive regulator of erythroid differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8547631" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Opposing effects of the basic helix-loop-helix transcription factor SCL on erythroid and monocytic differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2034676" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7969446" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Chromosomal translocations in human cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8033210" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8078932" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7957052" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1370462" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8353273" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dynamics of GATA transcription factor expression during erythroid differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7689871" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504932" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ectopic expression of a conditional GATA-2/estrogen receptor chimera arrests erythroid differentiation in a hormone-dependent manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8078582" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : An early haematopoietic defect in mice lacking the transcription factor GATA-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24227816" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328281" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2320112" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2320113" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Megakaryocytic and erythrocytic lineages share specific transcription factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507862" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Expression of mRNA for the GATA-binding proteins in human eosinophils and basophils: potential role in gene transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174764" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Differential effects of GATA-1 on proliferation and differentiation of erythroid lineage cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1987478" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1302015" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7926723" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7867497" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Development of hematopoietic cells lacking transcription factor GATA-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7568185" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18258797" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ablation of Gata1 in adult mice results in aplastic crisis, revealing its essential role in steady-state and stress erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10700180" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12172547" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12586620" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14656875" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Natural history of GATA1 mutations in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22706301" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24952648" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Altered translation of GATA1 in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29551269" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097519" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Ribosomopathies: There's strength in numbers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411939" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7682653" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family of nuclear proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20676099" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20676097" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23474875" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Three fingers on the switch: Krüppel-like factor 1 regulation ofγ-globin toβ-globin gene switching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21055716" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24829204" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity ofβ-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24443441" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22093801" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Delayed fetal hemoglobin switching in subjects with KLF1 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25724378" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23894012" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Erythropoietin critically regulates the terminal maturation of murine and human primitive erythroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3511093" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/719172" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6432390" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Erythropoiesis in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16687716" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Lineage-specific hematopoietic growth factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2644985" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7553874" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10428030" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719363" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8506290" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7889566" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283061" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7508174" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The kit ligand, stem cell factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718487" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Diamond-blackfan anemia: in vitro response of erythroid progenitors to the ligand for c-kit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718488" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : In vitro growth and regulation of bone marrow enriched CD34+ hematopoietic progenitors in Diamond-Blackfan anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718489" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Diamond-Blackfan anemia: heterogenous response of hematopoietic progenitor cells in vitro to the protein product of the steel locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2473008" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7545788" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Interaction of the erythropoietin and stem-cell-factor receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292519" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2651478" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Human colony-forming units-erythroid do not require accessory cells, but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6336950" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Insulin stimulates erythroid colony formation independently of erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2113615" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Identification of a potent Xenopus mesoderm-inducing factor as a homologue of activin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2920215" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Characterization of the potentiation effect of activin on human erythroid colony formation in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24710373" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Targeting a new regulator of erythropoiesis to alleviate anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24658077" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : An activin receptor IIA ligand trap corrects ineffective erythropoiesis inβ-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570654" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The use of luspatercept for thalassemia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33511859" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Luspatercept in the treatment of lower-risk myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17588470" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : MicroRNA expression dynamics during murine and human erythroid differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20216213" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : MicroRNAs in erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21196494" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : miR-191 regulates mouse erythroblast enucleation by down-regulating Riok3 and Mxi1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330772" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303114" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A GATA-1-regulated microRNA locus essential for erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19911427" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849488" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679397" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679398" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1557429" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Erythropoietin: structure, control of production, and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8318914" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Regulation of the erythropoietin gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8440337" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Regulation of erythropoietin production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9510530" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Erythropoietin: a model system for studying oxygen-dependent gene regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494350" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539918" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7836384" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Purification and characterization of hypoxia-inducible factor 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830968" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Oxygen sensing, homeostasis, and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9653127" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10823831" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209156" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Molecular basis of the VHL hereditary cancer syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11595178" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11292861" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11292863" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Signal transduction. How do cells sense oxygen?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11292862" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12415268" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16407130" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184961" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : A gain-of-function mutation in the HIF2A gene in familial erythrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15626745" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19809162" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8089148" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15026807" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15975138" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : VHL: oxygen sensing and vasculogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15374877" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17557118" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074486" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1924331" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1448072" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7891708" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917528" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : An essential role for p300/CBP in the cellular response to hypoxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406725" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13003537" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Fundamental stimulus for erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2539263" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Expression cloning of the murine erythropoietin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6095306" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2546618" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Receptors for erythropoietin in mouse and human erythroid cells and placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3192618" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2536329" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Binding of iodinated erythropoietin to rat bone marrow cells under normal and anemic conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13792901" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Cellular kinetics and iron utilization in bone marrow as observed by Fe59 radioautography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6181096" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Synthesis of hemoglobin F in adult simian erythroid progenitor-derived colonies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2580859" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Determination of the hemoglobin F program in human progenitor-derived erythroid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/429549" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Production of erythrocytes that contain fetal hemoglobin in anemia. Transient in vivo changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/719166" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Augmentation of fetal hemoglobin (HbF) synthesis in culture by human erythropoietic precursors in the marrow and peripheral blood: studies in sickle cell anemia and nonhemoglobinopathic adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/476302" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Hemoglobin synthesis in human BFU-E and CFU-E-derived erythroid colonies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/268643" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21060151" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Murine erythroid short-term radioprotection requires a BMP4-dependent, self-renewing population of stress erythroid progenitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18927434" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Maintenance of the BMP4-dependent stress erythropoiesis pathway in the murine spleen requires hedgehog signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177435" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : HIF1alpha synergizes with glucocorticoids to promote BFU-E progenitor self-renewal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21527522" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30827895" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Rate of Progression through a Continuum of Transit-Amplifying Progenitor Cell States Regulates Blood Cell Production.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
